The FDA’s approval of Kisunla demonstrates a positive change in Alzheimer disease management. Offering illness pathology therapy and the option of treatment conclusion after reaching therapeutic goals ...

That has changed recently after he Food and Drug Administration gave its approval to two new medications, lecanemab in July ...

Boosting a certain brain protein could help slow the progression of Alzheimer’s disease, a new study has found. The ...

Mohit Bansal, an analyst from Wells Fargo, maintained the Hold rating on Biogen (BIIB – Research Report). The associated price target ...

The Western New York Chapter of the Alzheimer’s Association will offer a free education program on recognizing and understanding Alzheimer’s disease and dementia at 10 a.m. Thursday at ...

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been ...

Researchers have discovered that Alzheimer's drugs Leqembi and Kisunla boost levels of a healthy form of protein in the brain, even as they reduce its more toxic form.

Large drug-maker stocks have witnessed a strong run this year, driven by positive pipeline news and regulatory approvals. The ...

It was hailed as the "beginning of the end" for Alzheimer's disease back in November 2022. The results of a Phase Three clinical trial published in the prestigious New England Journal of Medicine ...

For the FDA-approved donanemab, it appears that baseline amyloid load best predicts when to stop dosing, and that it may tell the doctor what the right time point might be to confirm with a second PET ...

Eli Lilly's Donanemab has shown greater effectiveness in slowing cognitive decline than Biogen/Eisai's lecanemab. NICE previously cited lecanemab's annual cost—between £50,000 and £100,000 per ...

Since then, two other anti-amyloid antibodies, Biogen’s lecanemab and Eli Lily’s donanemab, have demonstrated an ability to slow cognitive decline in individuals with early Alzheimer’s ...